Ray Dalio's BMRN Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 229,961 shares of BioMarin Pharmaceutical Inc. (BMRN) worth $13.67 M, representing 0.05% of the portfolio. First purchased in 2014-Q1, this long-term strategic position has been held for 24 quarters.
Based on 13F filings, Ray Dalio has maintained a strategic position in BMRN, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 160,166 shares. Largest reduction occurred in Q1 2024, reducing 187,604 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's BioMarin Pharmaceutical (BMRN) Holding Value Over Time
Track share changes against reported price movement
Quarterly BioMarin Pharmaceutical (BMRN) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -145,722 | Reduce 38.79% | 229,961 | $59.43 |
| Q3 2025 | +147,937 | Add 64.96% | 375,683 | $54.16 |
| Q2 2025 | +104,090 | Add 84.18% | 227,746 | $54.97 |
| Q1 2025 | -178,824 | Reduce 59.12% | 123,656 | $70.69 |
| Q4 2024 | +160,166 | Add 112.54% | 302,480 | $65.73 |
| Q3 2024 | +107,330 | Add 306.80% | 142,314 | $70.29 |
| Q2 2024 | +31,618 | Add 939.33% | 34,984 | $82.33 |
| Q1 2024 | -187,604 | Reduce 98.24% | 3,366 | $87.34 |
| Q4 2023 | +29,576 | Add 18.33% | 190,970 | $96.42 |
| Q3 2023 | +11,418 | Add 7.61% | 161,394 | $88.48 |
| Q2 2023 | +25,932 | Add 20.91% | 149,976 | $86.68 |
| Q1 2023 | +17,665 | Add 16.61% | 124,044 | $97.24 |
| Q4 2022 | -1,165 | Reduce 1.08% | 106,379 | $103.49 |
| Q3 2022 | +67,829 | Add 170.79% | 107,544 | $84.77 |
| Q2 2022 | +20,065 | Add 102.11% | 39,715 | $82.87 |
| Q1 2022 | +5,667 | Add 40.53% | 19,650 | $77.10 |
| Q4 2021 | -27 | Reduce 0.19% | 13,983 | $88.32 |
| Q3 2021 | -9,171 | Reduce 39.56% | 14,010 | $77.30 |
| Q2 2021 | +9,743 | Add 72.50% | 23,181 | $83.43 |
| Q1 2021 | +13,438 | New Buy | 13,438 | $75.53 |
| Q4 2016 | -8,926 | Sold Out | 0 | $0.00 |
| Q3 2016 | +8,926 | New Buy | 8,926 | $92.54 |
| Q2 2014 | -48,400 | Sold Out | 0 | $0.00 |
| Q1 2014 | +48,400 | New Buy | 48,400 | $68.20 |
Ray Dalio's BioMarin Pharmaceutical Investment FAQs
Ray Dalio first purchased BioMarin Pharmaceutical Inc. (BMRN) in Q1 2014, acquiring 48,400 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held BioMarin Pharmaceutical Inc. (BMRN) for 24 quarters since Q1 2014.
Ray Dalio's largest addition to BioMarin Pharmaceutical Inc. (BMRN) was in Q4 2024, adding 302,480 shares worth $19.88 M.
According to the latest 13F filing for Q4 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 229,961 shares of BioMarin Pharmaceutical Inc. (BMRN), valued at approximately $13.67 M.
As of the Q4 2025 filing, BioMarin Pharmaceutical Inc. (BMRN) represents approximately 0.05% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in BioMarin Pharmaceutical Inc. (BMRN) was 375,683 shares, as reported at the end of Q3 2025.